摘要
目的:分析复方苦参注射液联合放疗对老年中晚期食管癌患者的临床应用价值.方法:选取 2020 年 3 月～2023 年 3 月某院收治的 70 例老年中晚期食管癌患者作为研究对象,按照随机数字表法分为对照组和观察组,每组 35 例.对照组采用放疗,观察组在对照组基础上采用复方苦参注射液治疗.比较两组患者临床疗效、T淋巴细胞亚群水平(CD3+、CD4+、CD8+)、血清肿瘤标志物水平[癌胚抗原(CEA)、糖类抗原 50(CA50)、糖类抗原125(CA125)、糖类抗原199(CA199)、鳞状细胞癌抗原(SCCA)]、辅助性T淋巴细胞 17(Th17)比例、白介素-17(IL-17)水平、生活质量评分和不良反应发生情况.结果:观察组患者疾病控制率(74.29%)高于对照组(51.43%,P＜0.05).治疗后,两组患者CD3+、CD4+均升高,且观察组高于对照组;CD8+、CEA、CA50、CA125、CA199、SCCA、Th17 比例、IL-17 水平、生活质量评分均降低,且观察组低于对照组(P＜0.05).治疗期间,观察组患者不良反应总发生率(17.14%)低于对照组(40.00%,P＜0.05).结论:复方苦参注射液联合放疗可提高老年中晚期食管癌患者的临床治疗效果和生活质量,改善免疫功能,下调肿瘤标志物表达,且能减少不良反应的发生.
Abstract
Objective:To analyze the clinical application value of compound Kushen injection combined with radiotherapy in elderly patients with advanced esophageal cancer.Methods:A total of 70 elderly patients with advanced esophageal cancer treated in a hospital from March 2020 to March 2023 were selected and assigned to the control group and observation group by random number table,with 35 patients in each group.The control group was treated with radiotherapy,and the observation group was treated with compound Kushen injection in addition to the treatment given in the control group.The clinical efficacy,levels of T lymphocyte subsets(CD3+,CD4+,CD8+),levels of serum tumor markers[carcinoembryonic antigen(CEA),carbohydrate antigen 50(CA50),carbohydrate antigen 125(CA125),carbohydrate antigen 199(CA199),squamous cell carcinoma antigen(SCCA)],proportion of T helper cell 17(Th17),interleukin-17(IL-17)level,quality of life score and incidence of adverse reactions were compared between the two groups.Results:The disease control rate in the observation group(74.29% )was higher than that in the control group(51.43%,P<0.05).After treatment,CD3+and CD4+in both groups were increased,with the observation group showing higher levels than the control group,while CD8+,CEA,CA50,CA125,CA199,SCCA,proportion of Th17,IL-17 level and quality of life score were all decreased,with the observation group showing lower levels than the control group(P<0.05).During the treatment,the total incidence of adverse reactions in the observation group(17.14% )was lower than that in the control group(40.00%,P<0.05).Conclusion:Compound Kushen injection combined with radiotherapy can improve the clinical efficacy and quality of life in elderly patients with advanced esophageal cancer,improve immune function,down-regulate the expression of tumor markers,and reduce the incidence of adverse reactions.
维普
万方数据